
Keywords: Atypical hemolytic uremic syndrome; Complement; Eculizumab; Terminal complement inhibitor; Thrombotic microangiopathy; AH50; Alternative pathway function; TMA; Thrombotic microangiopathy; HUS; Hemolytic uremic syndrome; aHUS; Atypical HUS; LDH; Lactate de